Page last updated: 2024-12-09

1-(1,3-benzodioxol-5-yl)-3-(3-pyridinylmethyl)urea

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

1-(1,3-benzodioxol-5-yl)-3-(3-pyridinylmethyl)urea is a chemical compound that has been investigated for its potential medicinal properties, particularly as a **kinase inhibitor**.

Here's a breakdown:

**1. Chemical Structure:**

* **1,3-benzodioxol-5-yl:** This part of the molecule is a substituted benzene ring with a five-membered ring containing two oxygen atoms.
* **3-pyridinylmethyl:** This part is a substituted pyridine ring attached to a methylene group (CH2).
* **Urea:** The urea group (-NH-CO-NH-) connects the two aforementioned parts.

**2. Biological Activity:**

The compound is known to exhibit **kinase inhibitory activity**. Kinases are enzymes that play crucial roles in cellular signaling pathways by transferring phosphate groups to other molecules. This process is essential for many cellular functions, and abnormal kinase activity is implicated in various diseases, including cancer.

**3. Research Significance:**

* **Cancer Treatment:** The kinase inhibitory activity of 1-(1,3-benzodioxol-5-yl)-3-(3-pyridinylmethyl)urea makes it a potential candidate for the development of anticancer drugs.
* **Other Therapeutic Applications:** Research suggests that the compound may also be effective in treating other conditions, such as inflammatory diseases and neurological disorders, due to its influence on various signaling pathways.

**4. Research Focus:**

Current research on this compound focuses on:

* **Target identification:** Identifying the specific kinases that are inhibited by the compound.
* **Mechanism of action:** Understanding how the compound interacts with the target kinases to inhibit their activity.
* **Drug development:** Optimizing the compound's properties for improved efficacy, safety, and bioavailability to develop a potential drug candidate.

**Overall, 1-(1,3-benzodioxol-5-yl)-3-(3-pyridinylmethyl)urea is an interesting chemical compound with potential therapeutic applications, particularly in the field of cancer treatment. Further research is ongoing to explore its full potential.**

Cross-References

ID SourceID
PubMed CID971608
CHEMBL ID1452616
CHEBI ID112402

Synonyms (14)

Synonym
n-1,3-benzodioxol-5-yl-n'-(3-pyridinylmethyl)urea
MLS000671940
smr000294448
STK458025
1-(1,3-benzodioxol-5-yl)-3-(pyridin-3-ylmethyl)urea
CHEBI:112402
AKOS003346049
HMS2675J23
CHEMBL1452616
1-(1,3-benzodioxol-5-yl)-3-(3-pyridinylmethyl)urea
Q27192506
SR-01000278729-1
sr-01000278729
n-(1,3-benzodioxol-5-yl)-n'-(3-pyridylmethyl)urea
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
benzodioxoles
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (5)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
LuciferasePhotinus pyralis (common eastern firefly)Potency37.93300.007215.758889.3584AID588342
ATAD5 protein, partialHomo sapiens (human)Potency26.09040.004110.890331.5287AID504466; AID504467
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency79.43280.035520.977089.1251AID504332
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency25.11890.050127.073689.1251AID588590
gemininHomo sapiens (human)Potency0.51740.004611.374133.4983AID624297
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]